Back to homepage Our offer: Antimicrobials

Experts in the fight against infectious diseases and epidemiological monitoring

Aware of the major issue represented by antibiotic and antifungal resistance, as well as the essential need to develop new antimicrobial strategies, Smaltis and its founders have been combating this scourge for over 15 years. Through its R&D work and innovative tools, Smaltis is committed to sharing its expertise in the field, assisting you in the development of your anti-infective candidates, and participating in epidemiosurveillance studies in the One Health context.

Enhance the value of your products by entrusting them to recognized experts

Whether your products are derived from chemistry, nature, microorganisms, bacteriophages, accelerate and ensure their development by entrusting them to our laboratories:

  • Antibiotics
  • Antifungals
  • Antimicrobial peptides
  • Strains with antimicrobial properties
  • Bacteriophages
  • Vaccines
  • Antibodies
  • Hygiene and disinfection products
  • Any other compound with antimicrobial purposes

A comprehensive and precise offering to support your anti-infective programs

From research phases to epidemiosurveillance studies








Screening and selection of the most promising candidates,
Efficacy validation,
Identification of mechanisms of action,
Cytotoxicity studies

Anticipation of resistance that will emerge in clinical isolates,
Identification of resistance mechanisms whether known or unknown, that these isolates will use to adapt

Monitoring the evolution of the proportion of microorganisms resistant to a molecule and the associated resistance mechanisms


Determination of antimicrobial efficacy and spectrum of action,
Description of mechanisms of action,
Evaluation of cytotoxic potential

Study of resistance evolution through successive passages,
Determination of the frequency of appearance of resistant mutants,
Identification of involved resistance mechanisms

Centralization and identification of strains,
Determination of their level of resistance to target molecules,
Description of involved resistance mechanisms

Our promise: expertise and know-how to validate and secure your developments

The development of antimicrobial products requires expertise and rigor, skills recognized at Smaltis. Our researchers accompany you with tried and tested solutions, unique tools, and informed scientific advice to overcome challenges in finding alternatives to existing antimicrobial solutions. From research stages to epidemiosurveillance studies, we work hand in hand with your teams to obtain reliable data and address the constant evolution of microorganisms.

The founders and researchers at Smaltis completed their PhDs in the field of antibiotic resistance, particularly in understanding resistance mechanisms employed by the bacterial species Pseudomonas aeruginosa. In this context, they have conducted numerous research projects contributing to the advancement of knowledge related to the fight against infections and antibiotic resistance.

The researchers at the Smaltis team are among the authors of over 50 scientific articles published in international journals related to the development of antimicrobials and the study of resistance mechanisms.

Since the beginning, Smaltis has been building specific proprietary mutant banks in various species such as Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae, presenting different and characterized antibiotic resistance profiles in perfectly controlled genetic backgrounds. These strain banks facilitate the understanding of known resistance mechanisms and help anticipate the adaptation of microorganisms to future antimicrobial molecules.

Smaltis and the Technological Research Institute Bioaster have joined forces in an exclusive collaboration to offer a unique tool to facilitate the development of new antibiotic molecules by predicting their antibacterial mechanism of action. An offering is currently in development… stay tuned!

For over 15 years, members and founders of Smaltis have surrounded themselves with experts in the field of combating antibiotic resistance, benefiting from strong scientific support, such as the National Reference Center for Antibiotic Resistance led by Professor Katy JEANNOT and the Biological Resources Center of the Jean Minjoz University Hospital in Besançon. To maintain its expertise, Smaltis regularly attends specialized conferences in the field to stay informed about advances and key issues.

They trust us

Testimonials and references

Agustina LLANOS
Head of Biology

We have collaborated with Smaltis on several occasions since 2014, notably as part of our ANT3273 project. This is an inhaled medicine targeting a key virulence factor of Pseudomonas aeruginosa involved in pathogenesis and would be an alternative or complement to existing antibiotic therapy for the treatment of P. aeruginosa infections in chronic respiratory diseases, such as bronchiectasis. Recently, Smaltis successfully completed a MLST sequencing project of a large number of strains with a very tight timeline to study the clonality of clinical isolates of P. aeruginosa from cystic fibrosis patients. The Smaltis team stands out for its expertise, proactive approach, and its communication and adaptability, which is why we continue to trust them.

Head of Infection

The advancement of Technophage's therapeutic pipeline products has received crucial support from SMALTIS in the scope of genetic modification of bacterial strains. Throughout this collaborative effort, the SMALTIS scientific team has demonstrated remarkable commitment to resolving various technical challenges, successfully aligning with our objective of acquiring a set of strains for our internal utilization, all within the stipulated timeline.


As part of our anti-infective molecule developments, we have repeatedly sought the expertise of the Smaltis team for cloning and construction of specific mutants. The services provided by Smaltis have notably contributed to our study describing and characterizing new mechanisms of resistance to Odilorhabdines in Klebsiella pneumoniae, which was published in 2021. We know that we can rely on their know-how and expert scientific advice for our future developments.

Director of Pharmaceutical Development

During our program to develop and industrialize the production of our Kinoïdes® vaccines, SMALTIS has proven to be a partner of choice for optimizing one of our cytokine production systems. Its service consisted in optimizing the genetic heritage of the host bacterium by excising DNA from exogenous sequences. Very attentive and with a rare expertise in microbiology, the SMALTIS team has always been benevolent and has never hesitated to guide us by providing sound advice. It is with pleasure that we will again call upon the services of SMALTIS to help us in our next challenges.

Delphine GALLAND
Head of Preclinical Clinical Studies

For the past 10 years, we have regularly turned to Smaltis for their services and expertise in microbiology, cellular biology, and molecular biology. The entrusted work focused on evaluating the efficacy and safety of various products related to infectious diseases. The smoothness of our interactions, the responsiveness of the entire team, and their adaptation to our regulatory requirements have allowed us to advance our research projects optimally. The trust we have placed in Smaltis over these 10 years has led us to include this provider among our preferred contacts.

Co-founder and Scientific Director

Smaltis is an important partner for us, with whom we have established a close and early relationship to support the development of our new anti-infective molecules. We sought their recognized expertise in the field of antimicrobials and antibiotic resistance to support our proof of concept of the efficacy of our compounds, using specific strains from their mutant collection. With the help of growth kinetics, determination of Minimal Inhibitory Concentrations, and precise construction of mutant strains, along with their insightful advice and regular constructive exchanges, we obtained solid and essential elements to secure our data and continue our project.

News and articles


Smaltis attends the 34th edition of the ECCMID international congress, renamed ESCMID Global, in Barcelona from April 27 to 30, 2024. This clinical microbiology and infectious diseases event is one of the largest and most important congresses in the field of infection, bringing together over 16,000 participants from all over the world to contribute to the dissemination of scientific knowledge.


Sanofi Vaccines R&D Day

Smaltis attends the Sanofi Vaccines R&D Day, organized by Sanofi in partnership with Lyonbiopôle, Enosis Santé and Polepharma!
This event aims to foster partnerships around 5 themes: antimicrobial approaches, therapeutic vaccines and antibodies, mucosal or skin delivery of vaccines, immunology, and antigen design. Quite a program!

Cédric Muller will be present at this event, which will take place on April 11, 2024, at 14 Espace Henry Vallée in Lyon.


Viruses at the service of humanity?

Once upon a time, the English bacteriologist Ernest Hankin demonstrated for the first time the presence of anti-bacterial entities in the waters of Indian rivers, putting humanity on the path to a promising anti-infectious therapy that is more relevant than ever.


Microbiota & Health Day 7th edition

Smaltis is delighted to be taking part in the 7th edition of Microbiota & Health Day, organized by Lyonbiopôle and Alliance Promotion Microbiote, on March 26, 2024 in Lyon. The aim of this day is to bring together academic, clinical and industrial players to discuss topical issues that are driving innovation in the field of microbiota and their impact on health.


AMR Conference 8th edition

Smaltis is happy to participate to the 8th edition of AMR Conference in Basel from March 6th to 7th 2024, a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and specific challenges faced by the innovation ecosystem in bringing new antimicrobial treatments and diagnostics to the market.


The same… But better!

The year 2024 marks the 10th anniversary (already!) of the Smaltis adventure! 10 years of microbiology, 10 years of molecular biology, 10 years of passion, 10 years of twists and turns, 10 years of growth, 10 years of self-reflection, 10 years of continuous improvement, 10 years of scientific spirit, 10 years of ambition, 10 years of collaboration, 10 years of human relationships…

It was necessary to celebrate this milestone, and not just by blowing out the candles.


The Polepharma Microbiomics Days

Smaltis is delighted to have participated in and sponsored, for the fourth consecutive year, the Polepharma Microbiomics Days, held in Rouen on November 22 and 23, 2023.


The man who wanted to extend lifespan

Once upon a time, more than a century ago, Elie Metchnikoff hypothesized that health could be improved, and senility delayed by modulating the intestinal microbes thanks to bacteria present in yogurt. This zoologist and microbiologist was thus one of the first scientists to take an interest in gut microbiota and what we now call probiotics, the consumption of which he claimed helped to fight against aging.

This is the story of “the man who wanted to extend lifespan”.


All our sincere wishes

In this new year that begins, let’s take the time…

Let’s take the time to extend our best wishes to you, from the bottom of our hearts. It seems essential to us, during these periods conducive to gratitude, to prioritize human relationships as the most important aspect of our lives.